Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 15/20 | 0.69 |
| ▸ | NR1H4 | Q96RI1 | 13/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3420620 | 0.85 | EPHX2 (0.65) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL4618832 | 0.83 | EPHX2 (0.68) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL4403136 | 0.83 | EPHX2 (0.68) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL18232499 | 0.82 | EPHX2 (0.60) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL9784812 | 0.81 | CYP2C9 (0.59) | EPHX2NR1H4HDAC6CYP2C19CYP2C9 | |
| SCHEMBL9427403 | 0.81 | EPHX2 (0.59) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL16259478 | 0.81 | EPHX2 (0.47) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL4881592 | 0.81 | EPHX2 (0.61) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL11954 | 0.81 | EPHX2 (0.59) | EPHX2NR1H4HDAC3HDAC8HDAC6 | |
| SCHEMBL3897948 | 0.81 | CYP2C9 (0.59) | EPHX2NR1H4HDAC3HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035779-B2 | Prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2018-07-31 | — | — | US | disclosed |
| US-20160297772-A1 | PROLYL HYDROXYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-10-13 | — | — | US | disclosed |
| EP-2254860-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | Almirall, S.A. (ES) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009106351-A1 | DERIVATIVES OF 4-(2-AMINO-1-HYDROXYETHYL) PHENOL AS AGONISTS OF THE B2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297772-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | EPHX2 902/4885NR1H4 1287/4885HDAC3 3151/4885 |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | EPHX2 902/4885NR1H4 1287/4885HDAC3 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.